AMS on verge of win-win acquisition of Resorba for €64m
This article was originally published in Clinica
Advanced Medical Solutions (AMS), the UK company specialising in collagen-based wound closure products, has announced plans to acquire German wound care and wound closure specialist Resorba. The deal is for €64m ($86m), on a debt-free, cash-free basis to be paid, in full, on completion, entailing a £34m pre-emptive institutional placing and a €25m loan facility.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.